A 12-Week Safety and Pharmacodynamic Study of AT1001 in Patients With Fabry Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00283959
Recruitment Status : Completed
First Posted : January 31, 2006
Last Update Posted : April 15, 2015
Information provided by (Responsible Party):
Amicus Therapeutics

January 27, 2006
January 31, 2006
April 15, 2015
March 2006
May 2008   (Final data collection date for primary outcome measure)
Primary: Safety and tolerability. [ Time Frame: All visits ]
Primary: Safety and tolerability.
Complete list of historical versions of study NCT00283959 on Archive Site
Secondary: Pharmacodynamic and functional (cardiac, CNS/PNS, and renal) parameters. [ Time Frame: All visits ]
Secondary: Pharmacodynamic and functional (cardiac, CNS/PNS, and renal) parameters.
Not Provided
Not Provided
A 12-Week Safety and Pharmacodynamic Study of AT1001 in Patients With Fabry Disease
A Phase 2, Open-Label, Single Dose Level, 12-Week Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of AT1001 in Patients With Fabry Disease
The purpose of this study is to collect information on the safety of AT1001 (migalastat hydrochloride) and how AT1001 works in patients with Fabry disease.
The purpose of this study is to determine the effect of AT1001 given orally to patients with Fabry disease. Patients will visit the clinic 4 weeks prior to dosing to determine their eligibility for the study, and then return for a second visit for baseline and safety assessments, which will include skin, cardiac, and renal biopsies. Patients will receive oral doses of AT1001 for 12 weeks and will visit the clinic 3 more times, once every 4 weeks, for evaluation and tests. Skin, cardiac, and renal biopsies, and functional assessments will be performed at the end of the 12 week period. Patients may be given the opportunity to enter a study extension phase for an additional 36 weeks, which will require three more clinic visits, and a final set of functional tests and biopsies. All study participants will have a final follow up visit 2 weeks after the end of the study.
Phase 2
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Fabry Disease
Drug: AT1001 (migalastat hydrochloride)
administered every other day
Experimental: 150 mg capsule
oral migalastat HCl (AT1001) administered every other day.
Intervention: Drug: AT1001 (migalastat hydrochloride)

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
May 2008
May 2008   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Males between 18 and 65 years of age (inclusive)
  • Hemizygous for Fabry disease
  • Have a confirmed diagnosis of Fabry disease with a documented missense gene mutation (individual or familial)
  • Have enhanceable enzyme activity based on in vitro tests
  • Have documented evidence of cardiac and/or renal dysfunction (e.g., abnormal ECG, left ventricular hypertrophy, renal insufficiency)
  • Must be previously untreated by ERT or substrate depletion for Fabry disease and be willing to undergo two kidney, two cardiac, and three skin biopsies
  • Agree to be sexually abstinent or use a condom with spermicide when engaging in sexual activity during the course of the study and for a period of 30 days following their completion of the study
  • Willing and able to sign an informed consent form

Exclusion Criteria:

  • History of significant disease other than Fabry disease
  • History of organ transplant
  • Serum creatinine greater than 1.5 mg/dL on Day -2
  • Screening 12-lead ECG demonstrating QTc > 450 msec prior to dosing
  • Pacemaker or other contraindication for MRI scanning
  • Taking a medication prohibited by the protocol: Fabrazyme (agalsidase beta), Replagal (agalsidase alfa), Glyset (miglitol), Zavesca (miglustat), or any experimental therapy for any indication
  • Participated in a clinical trial in the last 30 days
  • Any other condition, which, in the opinion of the investigator, would jeopardize the safety of the patient or impact the validity of the study results
Sexes Eligible for Study: Male
18 Years to 65 Years   (Adult)
Contact information is only displayed when the study is recruiting subjects
Australia,   Brazil
AA1565521 (FAB-CL-202)
Not Provided
Not Provided
Not Provided
Amicus Therapeutics
Amicus Therapeutics
Not Provided
Principal Investigator: Roberto Giugliani, MD, PhD Serviço de Genética Médica, Hospital de Clínicas de Porto Alegre
Amicus Therapeutics
March 2015

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP